Department of Oncology, Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310009, Zhejiang Province, China.
World J Gastroenterol. 2011 Feb 14;17(6):809-16. doi: 10.3748/wjg.v17.i6.809.
To identify and assess mutations in the K-ras and BRAF genes in a cohort of Chinese patients with colorectal cancer (CRC) for their association with various clinicopathological parameters and prognosis.
Genomic DNA was isolated from frozen tissues. Pyrosequencing analysis was conducted to detect mutations in the K-ras (codons 12, 13, and 61) and BRAF genes (codon 600). Statistical analysis was carried out using SPSS-15.0 software.
Among the 118 colorectal cancer patients, we detected 41 (34.7%) mutations in the K-ras gene. Mutation frequencies at codon 12 and codon 13 were 23.7% (28/118) and 10.2% (12/118), respectively. Only one patient harbored a point mutation at codon 61 (0.8%, 1/118). Gender was the only factor that showed an obvious relationship with K-ras gene mutation (female 44.7% vs male 28.2%, P = 0.037). Other clinicopathological features, such as age, location of the tumor, tumor differentiation, Tumor, Node and Metastases classification, and the Union for International Cancer Control staging, showed no positive relationship with K-ras gene mutations. No significant correlation was observed between the presence of K-ras mutations (codons 12, 13, and 61) and the survival of the patients. BRAF mutations were rare, and only two patients (1.7%) harbored a detectable mutation at codon 600.
K-ras gene mutation is a common event in our 118 Chinese CRC patients, with an obvious relationship with gender. However, it seems not to be an independent prognostic factor in CRC patients. The BRAF gene is rarely mutated in Chinese CRC patients.
在一组中国结直肠癌(CRC)患者中鉴定和评估 K-ras 和 BRAF 基因的突变,以研究其与各种临床病理参数和预后的关系。
从冷冻组织中提取基因组 DNA。采用焦磷酸测序分析方法检测 K-ras(密码子 12、13 和 61)和 BRAF 基因(密码子 600)的突变。采用 SPSS-15.0 软件进行统计学分析。
在 118 例结直肠癌患者中,我们检测到 K-ras 基因有 41 例(34.7%)发生突变。密码子 12 和密码子 13 的突变频率分别为 23.7%(28/118)和 10.2%(12/118)。只有 1 例患者在密码子 61 发生点突变(0.8%,1/118)。性别是唯一与 K-ras 基因突变明显相关的因素(女性 44.7%比男性 28.2%,P=0.037)。其他临床病理特征,如年龄、肿瘤部位、肿瘤分化程度、肿瘤、淋巴结和转移分期、国际抗癌联合会分期等,与 K-ras 基因突变无明显相关性。未发现 K-ras 基因突变(密码子 12、13 和 61)与患者生存之间存在显著相关性。BRAF 基因突变罕见,仅 2 例患者(1.7%)在密码子 600 检测到可检测的突变。
K-ras 基因突变是本研究 118 例中国 CRC 患者中的常见事件,与性别明显相关。然而,它似乎不是 CRC 患者的独立预后因素。中国 CRC 患者 BRAF 基因很少发生突变。